Tesamorelin Research & Studies
We track 20 published, PubMed-indexed studies for Tesamorelin, spanning 2010 to 2026. The research below includes 1 meta-analysis, 5 reviews, 14 clinical trials.
These summaries are for educational purposes. Research findings, particularly from preclinical studies, may not translate to human outcomes. Always consult a qualified healthcare provider before making decisions based on this information.
1
Meta-Analysis
5
Reviews
14
Clinical Trials
Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials.
Meta-AnalysisBadran AS, Helal A, et al.|Obes Res Clin Pract|2026
Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.
ReviewRahman OF, Lee SJ, Seeds WA|J Am Acad Orthop Surg Glob Res Rev|2026
Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.
ReviewMayfield CK, Bolia IK, et al.|Am J Sports Med|2026
Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity.
Clinical TrialEllis RJ, Vaida F, et al.|J Infect Dis|2025
Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors.
Clinical TrialRusso SC, Ockene MW, et al.|AIDS|2024
Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD.
Clinical TrialFourman LT, Billingsley JM, et al.|JCI Insight|2020
Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial.
Clinical TrialStanley TL, Fourman LT, et al.|Lancet HIV|2019
The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV.
Clinical TrialAdrian S, Scherzinger A, et al.|J Frailty Aging|2019
Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial.
Clinical TrialClemmons DR, Miller S, Mamputu JC|PLoS One|2017
Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy subjects.
Clinical TrialGonzález-Sales M, Barrière O, et al.|Clin Pharmacokinet|2015
Predictors of Treatment Response to Tesamorelin, a Growth Hormone-Releasing Factor Analog, in HIV-Infected Patients with Excess Abdominal Fat.
Clinical TrialMangili A, Falutz J, et al.|PLoS One|2015
Population pharmacokinetic and pharmacodynamic analysis of tesamorelin in HIV-infected patients and healthy subjects.
Clinical TrialGonzález-Sales M, Barrière O, et al.|J Pharmacokinet Pharmacodyn|2015
The effects of tesamorelin on phosphocreatine recovery in obese subjects with reduced GH.
Clinical TrialMakimura H, Murphy CA, et al.|J Clin Endocrinol Metab|2014
Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial.
Clinical TrialStanley TL, Feldpausch MN, et al.|JAMA|2014
Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin.
Clinical TrialStanley TL, Falutz J, et al.|Clin Infect Dis|2012
Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy.
ReviewSpooner LM, Olin JL|Ann Pharmacother|2012
Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat: relationship with visceral adipose reduction.
Clinical TrialStanley TL, Falutz J, et al.|AIDS|2011
Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy.
ReviewDhillon S|Drugs|2011
Spotlight on tesamorelin in HIV-associated lipodystrophy.
ReviewDhillon S|BioDrugs|2011
Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension.
Clinical TrialFalutz J, Potvin D, et al.|J Acquir Immune Defic Syndr|2010